bioRxivCancer Biology
Pharmacological inhibition of nonsense-mediated RNA decay augments HLA class I-mediated presentation of neoepitopes in MSI CRC
J. P. Becker, D. Helm, M. Rettel, F. Stein, A. Hernandez-Sanchez, K. Urban, J. Gebert, M. Kloor, G. Neu-Yilik, M. von Knebel Doeberitz, M. W. Hentze, A. E. Kulozik
Abstract
Microsatellite-unstable (MSI) colorectal cancer is characterized by the accumulation of somatic insertion/deletion (InDel) mutations potentially generating tumor-specific, frameshifted protein sequences. Such mutations typically generate premature translation termination codons targeting the affected mRNAs to degradation by nonsense-mediated RNA decay (NMD), limiting the synthesis and HLA class I-mediated presentation of tumor-specific InDel neoepitopes. We reasoned that the NMD inhibitor 5-azacytidine (5AZA) could serve to increase the expression of NMD-sensitive neoepitopes and analyzed the immunopeptidome of MSI HCT-116 cells using a proteogenomic approach. After immunoprecipitation of HLA:peptide complexes, we identified more than 10,000 HLA class I-presented peptides by LC-MS/MS including five InDel neoepitopes. The InDel neoepitopes were verified on the genomic, transcriptomic, and peptidomic level. Treatment with 5AZA increased the expression of the corresponding frameshift- and premature termination codon-bearing mRNAs and enhanced the presentation of peptides originating from known NMD targets and one of the identified InDel neoepitopes. By analyzing an array of MSI colorectal cancer cell lines and patient samples, we found the underlying frameshift mutation to be highly recurrent and immunization with the corresponding neoepitope induced strong CD8+ T cell responses in an HLA-A*02:01 transgenic mouse model. Our data directly show that peptides originating from frameshifted open reading frames due to InDel mutations in mismatch repair-deficient cells are presented on the cell surface via HLA class I. Moreover, we demonstrate the utility of NMD inhibitor-enhanced HLA class I-mediated presentation of InDel neoepitopes as well as their immunogenicity, uncovering the clinical potential of NMD inhibition in anti-cancer immunotherapy strategies. One Sentence SummaryImmunopeptidomics identified increased HLA class I-mediated presentation of immunogenic, frameshift-derived neoepitopes following NMD inhibition.
- organism: human
- assay: proteomics
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Widespread immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors
V. Roudko, C. Cimen Bozkus, … N. Bhardwaj·bioRxiv·Jun 12, 2019
- Framing the potential of public frameshift peptides as immunotherapy targets in colon cancer
I. T. Spaanderman, F. S. Peters, … A. D. Bins·bioRxiv·Mar 26, 2020
- The shared neoantigen landscape of MSI cancers reflects immunoediting during tumor evolution
A. Ballhausen, M. J. Przybilla, … M. Kloor·bioRxiv·Jul 16, 2019
- Escape from nonsense mediated decay associates with anti-tumor immunogenicity
K. Litchfield, J. Reading, … C. Swanton·bioRxiv·Nov 14, 2019
- Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape
A. L. Cook, S. Sur, … N. Wyhs·bioRxiv·Dec 28, 2023
- Dual inhibition of the nonsense mediated mRNA decay enhances tumour immunogenicity, drives immunoediting, and potentiates checkpoint blockade
Ivan Zadra, Davor Orsolic, … Ana Janic·bioRxiv·Dec 8, 2025